NCT03298984View on ClinicalTrials.gov

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Alvocidib

IV bolus followed by IV infusion

DRUG

Cytarabine

continuous infusion

DRUG

Daunorubicin

IV bolus

Trial Locations (3)

10032

Columbia University, New York

21287

Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore

27599

University of North Carolina, Chapel Hill

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03298984 - Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | Biotech Hunter | Biotech Hunter